Intellia Therapeutics

NTLA48

$21.63arrow_drop_down1.97%-$0.43

NTLA48

$21.63

arrow_drop_down1.97%-$0.43

Performance History

Key Stats
Open	$21.14
Prev. Close	$20.67
EPS	-5.48
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	21.00	22.22
52 Week Range	19.21	37.15

Ratios







EPS	-5.48

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc (NTLA) is a leading biotechnology company focused on the development and commercialization of CRISPR/Cas9 genome editing technology. The company's goal is to harness the power of gene editing to develop potentially curative therapies for genetic diseases. Intellia is at the forefront of the CRISPR revolution, leveraging its proprietary platform to target a wide range of diseases with high unmet medical need. With a market cap of over $5 billion, Intellia Therapeutics is well positioned to capitalize on the growing demand for gene editing therapies in the healthcare industry.

Intellia Therapeutics has a strong track record of innovation and scientific expertise. The company's team of world-class researchers and scientists are dedicated to advancing the field of gene editing and translating their discoveries into transformative therapies. Intellia's proprietary platform enables precise and efficient editing of the human genome, offering the potential to correct disease-causing genetic mutations. By targeting specific genes and modifying their sequences, Intellia aims to develop breakthrough treatments for a wide range of genetic disorders, including rare diseases and cancer.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. John M. Leonard M.D.
Headquarters: Cambridge
Employees: 598
Exchange: NASDAQ

Keep an eye on Intellia Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Intellia Therapeutics 's (NTLA) price per share?

The current price per share for Intellia Therapeutics (NTLA) is $21.64. The stock has seen a price change of -$0.44 recently, indicating a -1.97% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Intellia Therapeutics (NTLA)?

For Intellia Therapeutics (NTLA), the 52-week high is $35.88, which is 65.84% from the current price. The 52-week low is $19.21, the current price is 12.62% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Intellia Therapeutics (NTLA) a growth stock?

Intellia Therapeutics (NTLA) has shown an average price growth of 0.41% over the past three years. It has received a score of 14 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Intellia Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Intellia Therapeutics (NTLA) stock price performance year to date (YTD)?

As of the latest data, Intellia Therapeutics (NTLA) has a year-to-date price change of -29.8%. Over the past month, the stock has experienced a price change of -5.4%. Over the last three months, the change has been -14.04%. Over the past six months, the figure is -23.55%. Looking at a longer horizon, the five-year price change stands at 47.78%.

help

Is Intellia Therapeutics (NTLA) a profitable company?

Intellia Therapeutics (NTLA) has a net income of -$481.19M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 75.26% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $36.28M, although specific revenue growth data is currently not available. The gross profit is $27.3M. Operating income is noted at -$515.29M. Furthermore, the EBITDA is -$514.18M.

help

What is the market capitalization of Intellia Therapeutics (NTLA)?

Intellia Therapeutics (NTLA) has a market capitalization of $2.24B. The average daily trading volume is 1.33M, indicating the stock's liquidity and investor engagement.